CERo, a medical research company, has shared some good news from their early tests of a new treatment called CER-1236 for a type of blood cancer called acute myeloid leukaemia (AML). This treatment uses specially modified immune cells to fight cancer. The first group of patients has completed the initial safety check, and so far, the treatment seems safe. The patients didn’t show any serious side effects like severe inflammation or neurological problems, which is a positive sign. One patient, who had a more advanced form of blood cancer that started from a condition called myelodysplastic syndrome (MDS), went 61 days without needing platelet transfusions after treatment. This is a big deal because usually, researchers look for at least eight weeks without transfusions to see if a treatment is working. This patient had a severe case, including a specific genetic problem called inv3. Because of these promising results, CERo has decided to include more types of blood cancers, like advanced MDS and myelofibrosis, in their study. They are also testing higher doses while continuing to check for safety and early signs of effectiveness. CER-1236 is designed to combine the best parts of two types of immune responses. It uses immune cells that can directly kill cancer cells and also cells that can ‘eat up’ harmful cells, which might help overcome some of the problems seen with current treatments for this type of cancer.